Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted radiopharmaceuticals for the diagnosis and treatment of cancer and rare diseases. The company leverages its expertise in molecular targeting and radioactive isotopes to design precision imaging agents and therapeutic compounds that bind to tumor-specific receptors, enabling physicians to visualize and treat malignancies at a cellular level.

Founded in 2015 and headquartered in Melbourne, Australia, Telix has expanded its footprint with offices in the United States, Europe and Asia. The company is led by CEO Christian Behrenbruch, who brings extensive experience in global biotechnology leadership. Telix is publicly traded on the Nasdaq under the ticker TLX and maintains its primary listing on the Australian Securities Exchange.

Telix operates a network of manufacturing and research facilities to support its clinical development programs and commercial launch activities. Its diagnostic imaging agent TLX591-CDx received marketing authorizations in both the United States (branded as Locametz) and the European Union (branded as Illuccix) for detecting prostate-specific membrane antigen (PSMA) in prostate cancer patients. The company collaborates with imaging centers and academic institutions worldwide to broaden access to its radiopharmaceutical solutions.

Beyond its lead diagnostic product, Telix’s pipeline includes therapeutic candidates such as TLX250 for renal cell carcinoma and TLX101 for rare central nervous system disorders. These programs are advancing through various stages of clinical evaluation, with the aim of delivering novel radiotherapeutic options that combine targeted delivery with the cytotoxic power of radioactive isotopes.

Key Stats

• Today's Range: $15.50 to $15.79
• 50-Day Range: $15.48 to $17.75
• 52-Week Range: $13.61 to $30.36
• Volume: 6,883 shs
• Average Volume: 29,015 shs
• Market Capitalization: $5.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.33
• Consensus Rating: Buy

TLX Stock Analysis - Frequently Asked Questions

How have TLX shares performed this year?

Telix Pharmaceuticals' stock was trading at $15.40 on January 1st, 2025. Since then, TLX shares have increased by 1.3% and is now trading at $15.5950.

When did Telix Pharmaceuticals IPO?

Telix Pharmaceuticals (TLX) raised $202 million in an IPO on Friday, June 14th 2024. The company issued 17,000,000 shares at $11.87 per share.

How do I buy shares of Telix Pharmaceuticals?

Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $22.33
• High Price Target: $23.00
• Low Price Target: $22.00
• Potential Upside/Downside: +42.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 2.78
• Quick Ratio: 2.66

Sales & Book Value

• Annual Sales: $516.72 million
• Price / Sales: 10.26
• Cash Flow: $0.11 per share
• Price / Cash Flow: 136.35
• Book Value: $1.12 per share
• Price / Book: 13.99

Miscellaneous

• Outstanding Shares: 338,380,000
• Free Float: N/A
• Market Cap: $5.30 billion
• Optionable: N/A
• Beta: N/A